BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Di Federico A, Mosca M, Pagani R, Carloni R, Frega G, De Giglio A, Rizzo A, Ricci D, Tavolari S, Di Marco M, Palloni A, Brandi G. Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes. Cancers 2022;14:2429. [DOI: 10.3390/cancers14102429] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Molnar A, Monroe H, Basri Aydin H, Arslan ME, Lightle A, Lee H, El Jabbour T. Tumors of the Digestive System: Comprehensive Review of Ancillary Testing and Biomarkers in the Era of Precision Medicine. Curr Oncol 2023;30:2388-404. [PMID: 36826143 DOI: 10.3390/curroncol30020182] [Reference Citation Analysis]
2 Tulyte S, Characiejus D, Matuzeviciene R, Janiulioniene A, Radzevicius M, Jasiunaite E, Zvirblis T, Sileikis A. Prognostic value of circulating T-lymphocyte subsets in advanced pancreatic cancer patients treated with mFOLFIRINOX or gemcitabine. International Immunopharmacology 2023;115:109722. [DOI: 10.1016/j.intimp.2023.109722] [Reference Citation Analysis]
3 Karakas D, Erkisa M, Akar RO, Akman G, Senol EY, Ulukaya E. Targeting Periostin Expression Makes Pancreatic Cancer Spheroids More Vulnerable to Natural Killer Cells. Biomedicines 2023;11. [PMID: 36830807 DOI: 10.3390/biomedicines11020270] [Reference Citation Analysis]
4 Mansouri S, Daniel L, Amhis N, Leveille M, Boudreau JE, Alkayyal AA, Collin Y, Tai LH. Perioperative oncolytic virotherapy to counteract surgery-induced immunosuppression and improve outcomes in pancreatic ductal adenocarcinoma. Front Oncol 2023;13:1071751. [PMID: 36874130 DOI: 10.3389/fonc.2023.1071751] [Reference Citation Analysis]
5 Hara K, Horikoshi Y, Morimoto M, Nakaso K, Sunaguchi T, Kurashiki T, Nakayama Y, Hanaki T, Yamamoto M, Sakamoto T, Fujiwara Y, Matsura T. TYRO3 promotes chemoresistance via increased LC3 expression in pancreatic cancer. Transl Oncol 2023;28:101608. [PMID: 36577166 DOI: 10.1016/j.tranon.2022.101608] [Reference Citation Analysis]
6 Chen X, Li J, Chen Y, Que Z, Du J, Zhang J. B7 Family Members in Pancreatic Ductal Adenocarcinoma: Attractive Targets for Cancer Immunotherapy. Int J Mol Sci 2022;23. [PMID: 36499340 DOI: 10.3390/ijms232315005] [Reference Citation Analysis]
7 Bravo-Vázquez LA, Frías-Reid N, Ramos-Delgado AG, Osorio-Pérez SM, Zlotnik-Chávez HR, Pathak S, Banerjee A, Bandyopadhyay A, Duttaroy AK, Paul S. MicroRNAs and long non-coding RNAs in pancreatic cancer: From epigenetics to potential clinical applications. Transl Oncol 2022;27:101579. [PMID: 36332600 DOI: 10.1016/j.tranon.2022.101579] [Reference Citation Analysis]
8 Loening F, Kleinwort A, Partecke LI, Schulze T, Menges P. Visceral Surgery Profoundly Affects the Cellular and Humoral Components of the Anti-Tumour Immune Response in a Murine Pancreatic Adenocarcinoma Model. Cancers 2022;14:3850. [DOI: 10.3390/cancers14163850] [Reference Citation Analysis]
9 Vay C, Babaei S, Safi SA, Dizdar L, Rehders A, Haeberle L, Roderburg C, Loosen SH, Esposito I, Knoefel WT, Krieg A. Clinicopathological and Prognostic Value of Survivin Expression in Surgically Resected Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2022;14. [PMID: 35884555 DOI: 10.3390/cancers14143494] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]